Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
15
pubmed:dateCreated
2006-4-12
pubmed:abstractText
Administration of daclizumab, a humanized mAb directed against the IL-2Ralpha chain, strongly reduces brain inflammation in multiple sclerosis patients. Here we show that daclizumab treatment leads to only a mild functional blockade of CD4(+) T cells, the major candidate in multiple sclerosis pathogenesis. Instead, daclizumab therapy was associated with a gradual decline in circulating CD4(+) and CD8(+) T cells and significant expansion of CD56(bright) natural killer (NK) cells in vivo, and this effect correlated highly with the treatment response. In vitro studies showed that NK cells inhibited T cell survival in activated peripheral blood mononuclear cell cultures by a contact-dependent mechanism. Positive correlations between expansion of CD56(bright) NK cells and contraction of CD4(+) and CD8(+) T cell numbers in individual patients in vivo provides supporting evidence for NK cell-mediated negative immunoregulation of activated T cells during daclizumab therapy. Our data support the existence of an immunoregulatory pathway wherein activated CD56(bright) NK cells inhibit T cell survival. This immunoregulation has potential importance for the treatment of autoimmune diseases and transplant rejection and toward modification of tumor immunity.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-10377437, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-10415039, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-11063837, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-11102772, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-11342442, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-11505971, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-11525803, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-11698225, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-11998892, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-12124859, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-12480696, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-12640450, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-12646619, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-14500636, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-14599854, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-15067033, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-15161974, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-15604218, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-15753206, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-1692080, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-1716974, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-2513570, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-7489743, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-7523571, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-8159750, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-8176234, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-8235625, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-9362528, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-9505189, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-9723424, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-9794841, http://linkedlifedata.com/resource/pubmed/commentcorrection/16585503-9851439
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD, http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD56, http://linkedlifedata.com/resource/pubmed/chemical/IL2RA protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Il2ra protein, mouse, http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G, http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2 Receptor alpha Subunit, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-2, http://linkedlifedata.com/resource/pubmed/chemical/daclizumab
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0027-8424
pubmed:author
pubmed:issnType
Print
pubmed:day
11
pubmed:volume
103
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5941-6
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:16585503-Animals, pubmed-meshheading:16585503-Antibodies, Monoclonal, pubmed-meshheading:16585503-Antibodies, Monoclonal, Humanized, pubmed-meshheading:16585503-Antigens, CD, pubmed-meshheading:16585503-Antigens, CD56, pubmed-meshheading:16585503-Disease Models, Animal, pubmed-meshheading:16585503-Humans, pubmed-meshheading:16585503-Immunoglobulin G, pubmed-meshheading:16585503-Immunosuppressive Agents, pubmed-meshheading:16585503-Inflammation, pubmed-meshheading:16585503-Interleukin-2, pubmed-meshheading:16585503-Interleukin-2 Receptor alpha Subunit, pubmed-meshheading:16585503-Killer Cells, Natural, pubmed-meshheading:16585503-Lymphocyte Activation, pubmed-meshheading:16585503-Lymphocyte Subsets, pubmed-meshheading:16585503-Mice, pubmed-meshheading:16585503-Mice, Knockout, pubmed-meshheading:16585503-Multiple Sclerosis, pubmed-meshheading:16585503-Receptors, Interleukin-2, pubmed-meshheading:16585503-T-Lymphocytes
pubmed:year
2006
More...